Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H4N2O4.C4H6N4O.2H2O |
Molecular Weight | 318.2435 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.NC(=O)C1=C(N)NC=N1.OC(=O)C2=CC(=O)NC(=O)N2
InChI
InChIKey=RAZMBRTXTADRMQ-UHFFFAOYSA-N
InChI=1S/C5H4N2O4.C4H6N4O.2H2O/c8-3-1-2(4(9)10)6-5(11)7-3;5-3-2(4(6)9)7-1-8-3;;/h1H,(H,9,10)(H2,6,7,8,11);1H,5H2,(H2,6,9)(H,7,8);2*1H2
Molecular Formula | C4H6N4O |
Molecular Weight | 126.1166 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C5H4N2O4 |
Molecular Weight | 156.0963 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17561451 | https://www.ncbi.nlm.nih.gov/pubmed/535326 | https://www.ncbi.nlm.nih.gov/pubmed/15120611
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17561451 | https://www.ncbi.nlm.nih.gov/pubmed/535326 | https://www.ncbi.nlm.nih.gov/pubmed/15120611
Orazamide, which is composed of one molecule of 5-aminoimidazole-4-carboxamide (AICA), one molecule of orotic acid and two molecules of water, is used clinically for the treatment of hepatitis and cirrhosis The nucleoside of AICA (AICAR) is internalized and becomes phosphorylated by adenosine kinase to form AICAR mono-phosphate (AICA ribotide, ZMP), an intermediate in the late steps of de novo purine biosynthesis. In hepatocytes, AICA can inhibit the fatty acid synthesis, sterol synthesis, and gluconeogenesis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111345 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15120611 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Orazamide Approved UseUnknown |
Sample Use Guides
treatment group orally administered with orazamide tablets 0.3 g,tid
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15120611
For analysis of TNF-alpha, macrophages were plated onto either 24-well or 6-well tissue culture plates. Cells (1.5x10^6 cells/ml) were treated with various concentrations (0.1, 0.5 and 1 mM) of AICAR (5-aminoimidazole-4-carboxamide) and LPS, as indicated. The quantity of TNF-a in culture supernatants was measured with an ELISA kit, according to the manufacturer’s instructions. The concentrations of TNF-a in each sample were calculated from a standard curve prepared using known concentrations of recombinant TNF- alpha.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:29:17 GMT 2023
by
admin
on
Sat Dec 16 04:29:17 GMT 2023
|
Record UNII |
7793E20Q84
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID60975528
Created by
admin on Sat Dec 16 04:29:17 GMT 2023 , Edited by admin on Sat Dec 16 04:29:17 GMT 2023
|
PRIMARY | |||
|
102285
Created by
admin on Sat Dec 16 04:29:17 GMT 2023 , Edited by admin on Sat Dec 16 04:29:17 GMT 2023
|
PRIMARY | |||
|
7793E20Q84
Created by
admin on Sat Dec 16 04:29:17 GMT 2023 , Edited by admin on Sat Dec 16 04:29:17 GMT 2023
|
PRIMARY | |||
|
m8226
Created by
admin on Sat Dec 16 04:29:17 GMT 2023 , Edited by admin on Sat Dec 16 04:29:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
60104-30-5
Created by
admin on Sat Dec 16 04:29:17 GMT 2023 , Edited by admin on Sat Dec 16 04:29:17 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE |